Summary box
1) What is already known on this subject? It has been shown that
uncontrolled inflammation and cytokine storm can cause death from
SARS-Cov-2. Blocking the release of cytokines and reducing inflammation
in stages two and three of the infection can be curative for the
patient.
2) What are the new findings? Colchicine blocks the upstream
inflammatory cascade compared to IL6 and IL1 inhibitors such as
tocilizumab / sarilumab and anakinra / canakinumab. It could also be
considered as monotherapy or in combination with these drugs.
3) How could it have an impact on clinical practice in the near future?
Using anti inflammatory and immunomodulatory drugs in the right doses
and timing, avoiding drug interactions can control the delicate
inflammatory/immune balance of the SARS-Cov-2 patient.
Keywords : colchicine, sars-cov-2, cytokine, interleukin,
coronavirus, pneumonia